Corticosteroids for IgA Nephropathy

20:00 EDT 31 Jul 2017 | JAMA

IgA nephropathy is the most common primary glomerular disease worldwide. In the United States, IgA nephropathy is second only to focal segmental glomerulosclerosis among primary glomerular diseases resulting in end-stage renal disease (ESRD), accounting for 13 012 new ESRD cases between 1996 and 2011. The clinical presentation is highly variable, ranging from synpharyngitic hematuria (ie, beginning within days of an upper respiratory tract infection), to asymptomatic microhematuria with or without proteinuria, to nephrotic syndrome, to rapidly progressive glomerulonephritis. However, ultimately more than one-third of patients with a biopsy-proven diagnosis of IgA nephropathy will progress to ESRD within 20 years, with attendant substantial morbidity, mortality, and health care utilization. Risk factors for progression to ESRD include uncontrolled hypertension, proteinuria in excess of 1 g/d, and an elevated serum creatinine level, with the presence of 1 of more of these factors a rationale for treatment initiation or patient inclusion in clinical trials.

Original Article: Corticosteroids for IgA Nephropathy


More From BioPortfolio on "Corticosteroids for IgA Nephropathy"

Quick Search

Relevant Topic

Nephrology - kidney function
Nephrology is a specialty of medicine and pediatrics that concerns itself with the study of normal kidney function, kidney problems, the treatment of kidney problems and renal replacement therapy (dialysis and kidney transplantation). Systemic conditions...